Glucoryl-M 1 Tablet PR is a combination oral antidiabetic medication containing Glimepiride 1 mg and Metformin 500 mg, indicated for the management of type 2 diabetes mellitus. Glimepiride, a sulfonylurea class agent, enhances pancreatic beta-cell insulin secretion, thereby reducing blood glucose levels. Metformin, a biguanide, primarily acts by decreasing hepatic glucose production and improving peripheral insulin sensitivity, facilitating increased glucose uptake by muscle cells. This synergistic combination addresses multiple pathophysiological defects in type 2 diabetes, promoting better glycemic control. Glucoryl-M 1 Tablet PR is prescribed as an adjunct to diet and exercise to improve glycemic parameters in patients inadequately controlled on monotherapy. The extended-release formulation ensures sustained plasma concentration, enhancing patient compliance and minimizing gastrointestinal side effects commonly associated with Metformin. Caution is advised in patients with renal impairment, hepatic dysfunction, or conditions predisposing to hypoxia, as these may increase the risk of lactic acidosis or hypoglycemia. Regular monitoring of blood glucose, renal function, and liver enzymes is recommended during therapy. Patients should be educated on recognizing symptoms of hypoglycemia and the importance of adherence to prescribed lifestyle modifications. Glucoryl-M 1 Tablet PR should be used under medical supervision with individualized dose adjustments based on therapeutic response.